Logo Image
Opinion|Videos|February 10, 2025

Navigating New Treatment Options for Pediatric Atopic Dermatitis Management

Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.

Episodes in this series

Video content above is prompted by the following:

  • Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
  • Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
  • JAK inhibitors: abrocitinib, baricitinib, upadacitinib

Related Content

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update
Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

View more
Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?
Video

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

View more